ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products. Subgroup L04 is part of the anatomical group L Antineoplastic and immunomodulating agents.
Contents
- L04AA Selective immunosuppressants
- L04AB Tumor necrosis factor alpha TNF inhibitors
- L04AC Interleukin inhibitors
- L04AD Calcineurin inhibitors
- L04AX Other immunosuppressants
- References
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL04.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
L04AA Selective immunosuppressants
L04AA02 Muromonab-CD3L04AA03 Antilymphocyte immunoglobulin (horse)L04AA04 Antithymocyte immunoglobulin (rabbit)L04AA06 Mycophenolic acidL04AA10 SirolimusL04AA13 LeflunomideL04AA15 AlefaceptL04AA18 EverolimusL04AA19 GusperimusL04AA21 EfalizumabL04AA22 AbetimusL04AA23 NatalizumabL04AA24 AbataceptL04AA25 EculizumabL04AA26 BelimumabL04AA27 FingolimodL04AA28 BelataceptL04AA29 TofacitinibL04AA31 TeriflunomideL04AA32 ApremilastL04AA33 VedolizumabL04AA34 AlemtuzumabL04AA35 BegelomabL04AA36 OcrelizumabL04AA37 BaricitinibL04AB Tumor necrosis factor alpha (TNF-α) inhibitors
L04AB01 EtanerceptL04AB02 InfliximabL04AB03 AfelimomabL04AB04 AdalimumabL04AB05 Certolizumab pegolL04AB06 GolimumabL04AC Interleukin inhibitors
L04AC01 DaclizumabL04AC02 BasiliximabL04AC03 AnakinraL04AC04 RilonaceptL04AC05 UstekinumabL04AC07 TocilizumabL04AC08 CanakinumabL04AC09 BriakinumabL04AC10 SecukinumabL04AC11 SiltuximabL04AC12 BrodalumabL04AC13 IxekizumabL04AC14 SarilumabL04AD Calcineurin inhibitors
L04AD01 CiclosporinL04AD02 TacrolimusL04AD03 VoclosporinL04AX Other immunosuppressants
L04AX01 AzathioprineL04AX02 ThalidomideL04AX03 MethotrexateL04AX04 LenalidomideL04AX05 PirfenidoneL04AX06 PomalidomideReferences
ATC code L04 Wikipedia(Text) CC BY-SA